Quintiles

What Quintiles does

Quintiles, founded in 1982 as a contract research organization, merged with IMS Health in 2016 and rebranded as IQVIA in 2017 following its NYSE IPO under ticker IQV. Today, IQVIA Inc. operates as a global life sciences services and technology platform with 10,000+ employees serving pharmaceutical manufacturers, emerging biopharma, MedTech, payers, providers, and government health agencies across 100+ countries. The company is structured around five solution areas — Research & Development (clinical trials, functional services, global labs), Real World Evidence, Commercialization, Safety & Regulatory Compliance, and Technologies — plus dedicated emerging biopharma support via the IQVIA Biotech sub-brand.

The technology backbone is the IQVIA Connected Intelligence framework, which integrates 64+ petabytes of proprietary healthcare data, 1.2B+ non-identified patient records, and coverage of 85% of global pharma sales with a portfolio of AI products. Notable technical assets include the Healthcare-grade AI framework, the IQVIA.ai Platform, agentic AI workflows, a proprietary Medical Reasoning LLM (Med-R1 8B), the IQVIA NLP Platform, the Clinical Trial Financial Suite, the IQVIA Vigilance Platform for pharmacovigilance, and AI-powered agents such as the Field Force Agent and Global Market Insights (GMI) Agent. Underlying products include Site Suite, Patient Engagement Suite, Safety Suite, SmartSolve eQMS/RIM, and orchestrated clinical trial planning and analytics suites.

IQVIA generates revenue through five primary streams: CRO professional services (project-based contracts for clinical development), technology licensing and platform subscriptions (Technology Solutions), data monetization and analytics consulting (Real World Evidence), commercialization professional services, and managed safety/regulatory compliance services. Pricing is quote-based under multi-year enterprise contracts; specific rates are not publicly disclosed. Distribution is anchored on direct enterprise field sales for large pharma and biotech, supplemented by an inside sales motion for mid-market emerging biopharma, partner programs, and a self-serve web channel for awareness and lead capture.

Name

Quintiles

Legal name

IQVIA Inc.

Website

https://quintiles.com

Company type

Public

Founded year

1982

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Quintiles (now IQVIA) is a publicly traded global life sciences services and technology platform offering clinical research, real-world evidence, commercialization, and regulatory compliance solutions, serving pharmaceutical manufacturers, emerging biopharma, MedTech, payers, and government agencies across 100+ countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Durham

HQ country

United States

HQ region

North America

Offices12 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Contract Research Organization (CRO) Services: Full-service clinical development including early phase trials, Phase IIb/III trials, patient & site centric solutions, functional services, global laboratories, and R&D consulting. Revenue generated through project-based contracts with pharmaceutical and biotech companies.
2. Technology Solutions: Platform-based solutions including Site Suite, Patient Suite, Clinical Trial Financial Suite, Safety Suite, Quality Management Suite, and commercial analytics tools. Revenue from technology licensing and platform subscriptions.
3. Real World Evidence & Analytics: Real world data, health data apps & AI, evidence networks, health economics & value, regulatory and safety services. Revenue from data licensing, analytics services, and consulting engagements.
4. Commercialization Services: Commercial effectiveness solutions including HCP engagement, patient engagement, brand strategy, launch management, and established brands optimization for pharmaceutical manufacturers.
5. Safety & Regulatory Compliance: End-to-end pharmacovigilance, regulatory compliance, quality compliance, medical information, and commercial compliance services.

Pricing tiers

Go-to-market motion1 record

Distribution channels6 records

Marketing channels7 records

Core offering

Quintiles (now IQVIA) is a contract research organization (CRO) that delivers biopharmaceutical development and commercial outsourcing services, including clinical trial design and execution, real world evidence generation, commercialization support, and safety/regulatory compliance. The company integrates 64+ petabytes of proprietary healthcare data with AI and analytics platforms such as IQVIA Connected Intelligence, Healthcare-grade AI, and the IQVIA.ai Platform to serve pharmaceutical manufacturers, biotech firms, healthcare providers, and government agencies across 100+ countries.

Product overview

IQVIA (formerly Quintiles) offers a comprehensive platform-plus-modules architecture spanning Research & Development, Real World Evidence, Commercialization, Safety & Regulatory Compliance, and Technologies. The core offering is built on IQVIA Connected Intelligence framework integrating 64+ petabytes of proprietary data with AI/ML capabilities. Key product lines include: IQVIA AI Platform and IQVIA Healthcare-grade AI for enterprise AI deployment; Agentic AI and IQVIA Medical Reasoning LLM for autonomous workflows and medical decision support; Field Force Agent and Global Market Insights Agent for commercial AI applications; Clinical technology suites (Patient Engagement Suite, Site Suite, Clinical Trial Financial Suite, Safety Suite, Quality Management and Regulatory Suite) for trial operations; and compliance products (IQVIA Vigilance Platform, SmartSolve RIM, SmartSolve eQMS) for pharmacovigilance and regulatory needs. IQVIA Biotech provides specialized clinical development for emerging biopharma. The platform processes 85% of global pharma sales tracked and operates across 100+ countries.

Differentiator

Problem solved

Functional benefit

Brands

• IQVIA Biotech: Full-service clinical development solutions with specialized, dedicated teams for smaller biotech companies.
• IQVIA AI
• IQVIA.ai Platform
• IQVIA Connected Intelligence
• IQVIA Vigilance Platform
• SmartSolve
• IQVIA Medical Reasoning LLM
• IQVIA Health Communications Group

Products and services

• IQVIA AI Platform

Quantifiable outcome

• 46% faster clinical trial site identification
• +2 more outcomes

Named customers1 record

Segments7 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature9 records

Partnerships

Four partnerships are on record, tiered flagship and core.

• Boehringer IngelheimflagshipStrategic or Co-development Partner · 1 January 2026Strategic long-term global commercial data foundation transformation collaboration announced January 2026. This partnership involves comprehensive data infrastructure transformation to support Boehringer Ingelheim's commercial operations globally.
• VeevacoreTechnology or Integration · 1 August 2025Long-term clinical and commercial partnerships with resolution of all disputes. Announced August 2025, this partnership covers both clinical trial management and commercial operations integration between the two platforms.
• NVIDIAflagshipTechnology or Integration · 1 June 2025IQVIA launched new AI agents for life sciences and healthcare in collaboration with NVIDIA. These AI agents are designed to enhance workflows and accelerate insights, representing a significant expansion of IQVIA's AI capabilities.
• NVIDIAflagshipTechnology or Integration · 1 January 2025Strategic collaboration to accelerate Healthcare-grade AI through NVIDIA technology. IQVIA is collaborating with NVIDIA to launch custom-built AI agents designed to enhance workflows and accelerate insights for life sciences and healthcare. This partnership creates new ways for customers to accelerate efforts to improve patient outcomes.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Labcorp (including Covance Drug Development): Labcorp owns Covance, one of the largest global CROs offering clinical development, central laboratory, and post-approval services. Directly comparable to IQVIA across Phase I–IV trials, central labs, and commercialization support, with similar scale and global footprint.
• ICON plc: ICON is a leading global CRO providing clinical research, consulting, and commercial services to pharma and biotech. Following its PRA Health Sciences acquisition, ICON is one of IQVIA's closest direct peers across full-service clinical development and bioanalytical labs.
• Parexel International: Parexel is a global CRO (owned by EQT/Goldman Sachs) providing Phase I–IV clinical development, regulatory, and biopharmaceutical services. Overlaps directly with IQVIA's clinical CRO and commercialization offerings, particularly for emerging biopharma.
• Syneos Health: Syneos Health is a fully integrated biopharmaceutical solutions organization offering clinical and commercial services. Direct peer to IQVIA across CRO services and commercialization, with comparable customer base and delivery model.
• Charles River Laboratories: Charles River Laboratories provides preclinical CRO services, discovery, safety assessment, and manufacturing support. Comparable to IQVIA's Global Laboratories and early-phase offerings, particularly in biotech and emerging biopharma segments.
• Medpace Holdings: Medpace is a mid-sized global CRO focused on Phase II–IV clinical development for small and mid-sized biopharma. Direct competitor to IQVIA Biotech and Quintiles' traditional mid-market CRO segment, with comparable therapeutic area expertise.

Broad incumbents

• Thermo Fisher Scientific (PPD): Thermo Fisher owns PPD, a top global CRO providing clinical development and laboratory services. Competes head-to-head with IQVIA in clinical research while Thermo Fisher's broader life sciences tools portfolio positions it as a broader incumbent with deeper vertical integration.
• Oracle Health Sciences (Clinical One / Cerner): Oracle provides clinical trial technology (Clinical One, eClinical), real world data, and healthcare analytics solutions. Competes with IQVIA's clinical technology suites and Connected Intelligence platform, with broader enterprise infrastructure reach.

Others

• Veeva Systems: Veeva provides cloud-based life sciences software for clinical, regulatory, and commercial operations. Despite prior disputes, Veeva and IQVIA announced a long-term partnership in 2025; their platforms are highly complementary and Veeva serves as a key technology peer to IQVIA's SmartSolve and clinical suites.

Emerging players

• WuXi AppTec: WuXi AppTec is a leading China-based CRO/CDMO providing preclinical, clinical, and biologics services. Comparable to IQVIA's global laboratories and clinical CRO offerings, particularly for biotech clients seeking Asia-based capacity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Quintiles
• Facebookfacebook.com/quintiles

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A19 records

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quintiles